Research Nester released a report titled “Huntington’s Disease Treatment Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global Huntington’s disease treatment market in terms of market segmentation by drug, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Huntington’s disease is a neurodegenerative disorder that occurs among middle aged people and becomes life-threatening after a period of about 20 years after its incidence. The market for Huntington’s disease treatment is estimated to grow by a significantly high CAGR during the forecast period, i.e., 2019-2027. The market is segmented by drug, by distribution channel and by region. On the basis of drug, the market is segmented into tetrabenazine, antidepressants, antipsychotic drugs, tranquilizers and others. On the other hand, based on distribution channel, the market is bifurcated into online and offline segments. The tetrabenazine drug segment is anticipated to witness a substantially high growth over the forecast period as a result of growing demand for this drug for the treatment of Huntington’s disease. Moreover, the ability of this drug to treat movement disorder and the rising research activities by leading companies for the development of tetrabenazine drugs are further predicted to result in the segment growth.

On the basis of region, the Huntington's disease treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is estimated to hold the largest market share in the upcoming years on account of growing research and development activities in the region. These are anticipated to lead to the development of highly effective and improved drugs for the treatment of this disorder, especially in the United States. The market in Europe is estimated to hold the second largest share in the market as a result of growing elderly population along with rising research and development activities.

Growing Patient Population for Huntington’s Disease to Impact the Market Growth

According to the Huntington’s disease Society of America, there are about 30,000 symptomatic people the United States, while over 200,000 people are at risk of inheriting the disease. The increasing cases of degenerative disorders affecting the nervous system is estimated to be a major growth driver for the Huntington’s disease treatment market. However, limited availability of approved drugs in the market as a result of strict government regulations is estimated to hamper the market growth during the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global Huntington’s disease treatment market which includes company profiling of Teva Pharmaceutical Industries Ltd. (TLV: TEVA), Pfizer Inc. (NYSE: PFE), Bausch Health Companies Inc. (NYSE: BHC), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Ceregene, Inc., SOM Biotech, Omeros Corporation (NASDAQ: OMER), H. Lundbeck A/S (CPH: LUN) and BioRep Srl. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Huntington’s disease treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.